potassium voltage-gated channel subfamily H member 2Genealiases: ERG-1 · ERG1 · H-ERG · HERG · HERG1 · Kv11.1
Q-omics provides the consensus-scored KCNH2 profile across patient tissues and cancer cell-line models. KCNH2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, KCNH2 is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, KCNH2 RNA expression shows 15,623 significant gene co-expression associations, with the highest sampling consensus in PCPG. Together, these results highlight ACC, BLCA, and PCPG as cancer lineages where KCNH2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KCNH2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KCNH2 survival associations across molecular data types. KCNH2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (10) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KCNH2 RNA expression–survival associations across cancer types. High KCNH2 expression shows unfavorable associations in UVM and UCEC, but favorable associations in ACC, HNSC, PAAD and LUAD. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for KCNH2 RNA expression.
This table summarizes KCNH2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in BLCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for KCNH2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KCNH2 shows lower tumor expression in BLCA, UCEC and STAD and higher tumor expression in BRCA, KIRP and KICH. The BLCA box plot shows higher KCNH2 RNA expression in normal versus tumor tissue (log2 FC = −4.572, t-test p < 0.001).
This table shows molecular features associated with KCNH2 in patient tissues and cancer cell lines. In patient samples, KCNH2 shows the broadest associations at the RNA and protein expression levels, with PCPG recurring as the lineage with the largest associated feature set. In cancer cell lines, KCNH2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
